Safe Treatments and Opportunities to Prevent Pain Act or the STOP Pain Act
This bill authorizes the National Institutes of Health (NIH) to intensify and coordinate NIH research into the understanding of pain, therapies for chronic pain, and alternatives to opioids (drugs with effects similar to opium) for pain treatments.
The prioritization and direction of federally funded pain research must consider recommendations made by the Interagency Pain Research Coordinating Committee.
[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5249 Introduced in House (IH)]
<DOC>
114th CONGRESS
2d Session
H. R. 5249
To direct the NIH to intensify and coordinate fundamental,
translational, and clinical research with respect to the understanding
of pain, the discovery and development of therapies for chronic pain,
and the development of alternatives to opioids for effective pain
treatments.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
May 16, 2016
Mrs. Capps (for herself, Mrs. Ellmers of North Carolina, Mr. McKinley,
and Ms. Matsui) introduced the following bill; which was referred to
the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To direct the NIH to intensify and coordinate fundamental,
translational, and clinical research with respect to the understanding
of pain, the discovery and development of therapies for chronic pain,
and the development of alternatives to opioids for effective pain
treatments.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Safe Treatments and Opportunities to
Prevent Pain Act'' or the ``STOP Pain Act''.
SEC. 2. ENHANCING BASIC AND APPLIED RESEARCH ON PAIN TO DISCOVER
THERAPIES, INCLUDING ALTERNATIVES TO OPIOIDS, FOR
EFFECTIVE PAIN MANAGEMENT.
(a) In General.--The Director of the National Institutes of Health
(referred to in this section as the ``NIH'') may intensify and
coordinate fundamental, translational, and clinical research of the NIH
with respect to--
(1) the understanding of pain;
(2) the discovery and development of therapies for chronic
pain; and
(3) the development of alternatives to opioids for
effective pain treatments.
(b) Priority and Direction.--The prioritization and direction of
the federally funded portfolio of pain research studies shall consider
recommendations made by the Interagency Pain Research Coordinating
Committee in concert with the Pain Management Best Practices Inter-
Agency Task Force, and in accordance with the National Pain Strategy,
the Federal Pain Research Strategy, and the NIH-Wide Strategic Plan for
Fiscal Years 2016-2020, the latter which calls for the relative burdens
of individual diseases and medical disorders to be regarded as crucial
considerations in balancing the priorities of the Federal research
portfolio.
<all>
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line